AQST:NSD-Aquestive Therapeutics Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 1.00

Change

-0.04 (-3.85)%

Market Cap

USD 0.04B

Volume

0.48M

Avg Analyst Target

USD 16.25 (+1,525.00%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aquestive Therapeutics Inc (AQST) Stock Analysis:
Based on the Aquestive Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Aquestive Therapeutics Inc is USD 16.25 over the next 12 months. Aquestive Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aquestive Therapeutics Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Aquestive Therapeutics Inc’s stock price was USD 1.00. Aquestive Therapeutics Inc’s stock price has changed by -17.36% over the past week, -50.00% over the past month and -70.85% over the last year.

About

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-1.89 (-2.19%)

USD8.24B 118.05 62.27
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-1.45 (-2.48%)

USD5.46B N/A N/A
PCRX Pacira BioSciences Inc

-2.46 (-3.90%)

USD2.89B 75.79 27.19
TLRY Tilray Inc

-0.23 (-5.12%)

USD2.35B 49.17 N/A
CGC Canopy Growth Corporation

-0.43 (-8.29%)

USD2.32B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

-0.30 (-2.64%)

USD1.75B 3.70 6.95
AMPH Amphastar Pharmaceuticals Inc

-0.86 (-2.47%)

USD1.70B 21.47 11.51

ETFs Containing AQST

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -74.29% 16% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.29% 16% F 7% F
Trailing 12 Months  
Capital Gain -70.41% 45% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.41% 45% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.08% 43% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.08% 41% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 49.13% 46% F 30% F
Risk Adjusted Return -16.44% 44% F 29% F
Market Capitalization 0.04B 30% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -1.32 51% F 58% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 172.74% 100% A+ 98% A+
Return on Assets -37.88% 17% F 8% F
Debt to Equity Ratio -62.76% 88% B+ 93% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.59 60% D- 45% F
Short Percent 4.49% 62% D- 37% F
Beta 3.40 4% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector